A new therapy from Bio Products Laboratory (BPL), a UK manufacturer of human blood plasma products, has become the first in Europe to be approved for treating patients with hereditary Factor X deficiency.

Following data from two open-label multicenter studies, Coagadex has been authorized for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with the deficiency.

Factor X deficiency is a rare and serious condition that affects around 700 people in Europe. It is caused by not having enough Factor X protein in the blood to promote clotting.

Until now, treatment has focused on blood infusions of plasma or a concentrate of clotting factors.

BPL CEO John Perkins said the medicine is the first of its kind for this disorder.